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Abstract
Background
Recurrent bleeding is one of the major causes of morbidity and mortality in patients with
aneurysmal subarachnoid hemorrhage (aSAH). Antifibrinolytic therapy is known to reduce
recurrent bleeding, however, its beneficial effect on outcome remains unclear. The effect of
treatment with tranexamic acid (TXA) until aneurysm treatment on clinical outcome is
evaluated.
Methods
Patients with an aSAH from two high-volume tertiary referral treatment centers in the Neth-
erlands, Academic Medical Center (AMC) and Radboud University Medical Center
(RUMC), between January 2012 and December 2015 were included. Patients were classi-
fied into one of two groups; standard treatment or TXA treatment. Demographic and clinical
characteristics, in-hospital complications and clinical outcome were compared between the
two groups. Multivariate logistic regression was used to adjust for the influence of treatment
center and baseline differences.
Results
Standard treatment was given in 509 patients, and 119 patients received additional TXA
therapy before aneurysm occlusion. Patients treated with TXA did not experience less recur-
rent bleeding adjusted or unadjusted for treatment center (adjusted odds ratio [aOR] 0.80,
95% confidence interval [95% CI]: 0.37–1.73). In-hospital mortality, was significantly lower
in the TXA group than the standard care group (adjusted OR [aOR] 0.42, 95% CI: 0.20–
0.85). Poor outcome (mRS 4–6) assessed after six months was not different between treat-
ment groups (aOR 1.05, 95% CI: 0.64–1.74).
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Conclusions
Pooled data from two high-volume treatment centers did not show improved clinical out-
come after additional TXA treatment in aSAH patients. However, TXA treatment was associ-
ated with a decrease in mortality.
Introduction
In the last decades, there is an increasing trend towards ultra-early (< 24 hours) aneurysm
occlusion to protect from recurrent bleeding after aneurysmal subarachnoid hemorrhage
(aSAH), as most recurrent bleedings occurs within a few hours after the initial bleeding[1], [2],
[3], [4], [5], [6]. In clinical practice, however, early treatment can be logistically challenging,
and therefore, is frequently delayed [7]. Based on Class IIa, level B evidence, the current AHA/
ASA guideline states that “short-term (<72 hours) therapy with tranexamic acid or aminoca-
proic acid is reasonable to reduce the risk of early aneurysm rebleeding”, and therefore, despite
a recent inconclusive Cochrane Database Systematic Review, some centers have incorporated
tranexamic acid (TXA) into their aSAH treatment protocols[8], [9], [10].
Inquiries among high-volume aSAH treatment centers in the Netherlands for participation
in a currently ongoing multicenter, randomized controlled trial[11] (RCT) revealed that one
treatment center included TXA administration prior to aneurysm occlusion in their protocol
for patients admitted to the Intensive Care Unit. To investigate whether TXA treatment
improves clinical outcome in a larger patient population, two prospective databases from two
university medical centers in the Netherlands were pooled and analyzed.
Methods
Patient population
Adult patients with aSAH from a prospective database, who were admitted between January
2012 and December 2015 to the Academic Medical Center (Amsterdam, the Netherlands;
AMC) and Radboud University Medical Center (Nijmegen, the Netherlands; RUMC), both
high-volume tertiary care centers, were included in this study if 1) subarachnoid hemorrhage
(SAH) was confirmed by a plain CT-scan on admission, or by presence of xanthochromia in
the cerebral spinal fluid, 2) a causative aneurysm was documented by CT-angiography (CTA)
and/or digital subtraction angiography (DSA), 3) onset of symptoms to admission was within
24 hours. Patients with SAH in whom an intracranial aneurysm could not be visualized, and
patients participating in an ongoing RCT were excluded from this analysis. The AMC patients
did not receive TXA, whereas the RUMC treatment protocol included TXA treatment before
aneurysm occlusion. Patients were classified into one of two groups (standard vs. TXA), based
on treatment with TXA.
Data collection
The results were reported according to the STROBE guidelines[12]. At baseline, the following
items were collected from our prospective database: demographic characteristics, World Fed-
eration of Neurosurgical Societies (WFNS) grade[13] on admission at the treatment center,
Fisher grade[14]. Furthermore, location of aneurysm, treatment modality (i.e. coiling or clip-
ping), time intervals (ictus-treatment, ictus-hospital admission, hospital admission-aneurysm
treatment), recurrent bleeding, per-procedural complications, systemic thromboembolic com-
plications, delayed cerebral ischemia (DCI), hydrocephalus, implantation of permanent shunt
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for cerebrospinal fluid diversion, in-hospital mortality, length of hospital stay (LOS), discharge
location and clinical outcome assessed after six months by the modified Rankin Scale (mRS),
using a standardized telephone interview by experienced specialized nurses, or on doctors’
experience and patient-reported functioning. Additionally, we performed a retrospectively
chart review to collected daily and total dosage of administered TXA. The study protocol was
approved by the local IRB’s and granted a waiver of consent.
Recurrent bleeding was defined as a second (or third etc.) bleeding from the causative aneu-
rysm after the initial bleeding. This was determined by an increase of blood on a plain CT-
scan of the head. Delayed cerebral ischemia was defined according to Vergouwen et. al.[15].
Hydrocephalus was defined either by enlarged ventricles on imaging, assessed by an experi-
enced neuroradiologist, or by increased intracranial pressure diagnosed by lumbar puncture
or ventricular catheter placement.
Treatment and clinical management
All patients were treated according to their hospital’s standardized protocols, which were
based mainly on the International Guidelines of 2009, including calcium antagonists (Nimodi-
pine), and hypertensive therapy and normovolemia when DCI was suspected; no rescue treat-
ment was initiated when hypertensive therapy failed. Blood pressure was lowered until
aneurysm occlusion using administration of short-acting, titratable, continuous intravenous
(IV) labetalol, if the mean arterial pressure was above 110mmHg and 135mmHg in the RUMC
and AMC, respectively. Patients who were treated with TXA received a loading dose of one
gram intravenously on admission to the emergency room or neurosurgical intensive care unit
of the RUMC, immediately followed by 1 gram as a continuous infusion over 8 hour intervals,
until occlusion of the causative aneurysm, or until a maximum of 36 hours. TXA treatment
was withheld in case of severe renal impairment (serum creatinin > 150 mmol/L. No TXA was
administered when patients went for aneurysm treatment immediately after presentation to
the emergency room. Ruptured aneurysms were treated as early as feasible (preferably within
24 hours after onset). An external ventricular or lumbar catheter was placed for CSF drainage
in case of hydrocephalus, or if raised intracranial pressure was suspected.
All patients were treated during admission with prophylactic nadroparin and compression
stockings until discharge.
Statistical analysis
The WFNS grades and mRS scores were dichotomized into good (WFNS grade 1–3) or poor
grade (WFNS grade 4–5), and into favorable (mRS 0–3) or poor (mRS 4–6) outcome. All other
endovascular treatments, i.e. web device, additional stenting or flow-diverter were classified
into coiling. Fisher grades were dichotomized into grade 0–3 and grade 4. Both prospective
databases (AMC / RUMC) were pooled and patients were allocated into one of two groups,
based on TXA treatment. Normally distributed variables, tested with the Shapiro Wilk test
(>0.9 is normally distributed), were expressed as means with standard deviations (SD) and
tested with the Student’s T test, and unequally distributed variables as medians with interquar-
tile ranges (IQR 25–75%) and tested with the Mann–Whitney U test. The Chi-square or Fish-
er’s exact test was used to assess differences in proportions wherever appropriate. Multivariate
logistic regression was used to take the combination of treatment center and TXA administra-
tion into account (three groups: AMC control, RUMC control, and RUMC TXA) and to adjust
for baseline differences. P-values< 0.05 were considered significant. Statistical analyses were
performed using the SPSS Statistics Software (IBM Corporation, New York, United States, ver-
sion 21).
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Results
Baseline demographics
Between January 2012 and December 2015, a total of 509 patients with an aSAH that met the
inclusions criteria, were admitted (Fig 1). In 390 (77%) patients no TXA was given (standard
treatment group, RUMC, n = 96; AMC, n = 294), whereas 119 (23%) patients received addi-
tional TXA treatment (TXA group, all RUMC).
Overall baseline data (Table 1) did not differ significantly between both groups.
The overall median time interval between onset of SAH and admission to treatment center
was three hours (IRQ 1–5), and was not significantly different between treatment groups.
Complications
Overall recurrent bleeding was 14% and occurred as often in the TXA group as in the standard
care group (13% and 14%, respectively). Procedural thrombus formation occurred slightly more in
the TXA group (12% in the TXA group and 9% in the standard group), not significant different.
No significant differences were seen in other per-procedural complications (rupture, treat-
ment ischemia). Use of TXA did not lead to a significantly increased rate of DCI, hydrocepha-
lus, or the need for a permanent shunt (Table 2). No systemic thromboembolic complications
occurred in the TXA group whereas three systemic thromboembolic complications occurred
in the standard group (one myocardial infarct, one atrial thrombosis and one pulmonary
embolism). There were also no significant differences between groups if complications were
compared between three groups (RUMC TXA, RUMC controls, and AMC controls).
Clinical outcome
In-hospital mortality was significantly lower in the TXA group (TXA group: 16%, standard
group: 25%; OR 0.57; 95% CI: 0.33–0.98). Poor outcome (mRS 4–6) at six months was not
Fig 1. Flowchart allocation per treatment group.
https://doi.org/10.1371/journal.pone.0211868.g001
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significantly different after adjusting and before adjusting for treatment centers and TXA
treatment (TXA group: 34%, standard group: 40%; OR 0.76; 95% CI: 0.48–1.18) (Table 3).
There were also no significant differences between groups if poor outcome was compared
between three groups (RUMC TXA, RUMC controls, and AMC controls).
Table 1. Baseline demographics of 509 patients with aneurysmal subarachnoid hemorrhage.
Characteristic TXA Group (%)
N = 119
Standard Group (%)
N = 390
Total (%)
N = 509
OR (95% CI)
Age in years, mean (SD) 58 (12) 57 (13) 57 (13) 1.01 (0.99–1.03)
Female 84 (71) 268 (69) 352 (70) 1.09 (0.70–1.71)
WFNS Grade
�
1.07 (0.71–1.63)
I-III 69 (58) 231 (60) 300 (59)
IV-V 50 (42) 156 (40) 206 (41)
Fisher Grade Scale
�
1.01 (0.71–1.45)
0–3 32 (27) 104 (27) 136 (27)
4 86 (73) 285 (73) 371 (73)
Causative aneurysm
location
�
0.98 (0.71–1.36)
Anterior circulation 75 (64) 245 (63) 320 (63)
Posterior circulation 43 (36) 144 (37) 187 (37)
Aneurysm treatment 1.16 (0.86–1.55)
None 12 (10) 61 (16) 73 (14)
Coiling 87 (73) 278 (71) 365 (72)
Clipping 20 (17) 51 (13) 71 (14)
Time intervals (hours)
aSAH to admission 2 (1–6) 3 (1–5) 3 (1–5) 1.02 (0.98–1.06)
aSAH to treatment% 13 (8–21) 9 (3–16) 9 (3–16) 1.00 (1.00–1.00)
Admission to treatment^ 13 (8–21) 12 (6–22) 13 (6–22) 1.00 (1.00–1.00)
aSAH to start TXA 5 (3–11) - 5 (3–11) -
SD = Standard deviation
�based on n = 507, %based on n = 410, ^based on n = 423, N (%) unless otherwise stated.
https://doi.org/10.1371/journal.pone.0211868.t001
Table 2. Complications per treatment group and adjusted per center with or without TXA treatment.
TXA Group
N = 119
Standard Group
N = 390
Total
N = 509
OR (95% CI) aOR (95% CI)
Recurrent bleeding
(N = 500)
15 (13) 53 (14) 68 (14) 0.97 (0.52–1.79) 0.80 (0.37–1.73)
Procedural rupture
(N = 423)
3 (3) 11 (3) 14 (3) 0.83 (0.23–3.04) 0.45 (0.11–1.95)
Delayed cerebral ischemia
(N = 503)
21 (18) 95 (25) 116 (23) 0.68 (0.40–1.15) 0.99 (0.49–2.00)
Treatment ischemia
(N = 426)
4 (4) 15 (5) 19 (5) 0.82 (0.27–2.52) 1.58 (0.28–8.85)
Procedural thrombus
(N = 425)
12 (12) 28 (9) 40 (9) 1.37 (0.67–2.79) 1.63 (0.58–4.55)
Hydrocephalus (N = 476) 63 (62) 223 (560) 286 (60) 1.13 (0.72–1.78) 1.33 (0.73–2.41)
N (%) unless otherwise stated.
https://doi.org/10.1371/journal.pone.0211868.t002
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Discussion
This study in patients with aneurysmal SAH compared treatment with TXA until aneurysm
repair to standard treatment, based on two pooled, prospective databases from high-volume
treatment centers in the Netherlands, with comparable treatment protocols. After adjusting
for treatment center and treatment, a significant decrease in in-hospital mortality was seen in
patients who were treated with TXA and poor outcome after six months was lower in patients
treated with TXA, compared to the standard treatment group, although without a statistical
difference.
Almost all recurrent bleedings occur within 24 h, with a median time interval between ini-
tial hemorrhage and recurrent bleeding of 180 min[1]. We recently showed that mortality was
significantly higher in patients with a recurrent bleeding, with less patients achieving a favor-
able outcome[1]. Thus, early occlusion of a ruptured aneurysm seems warranted. However,
because a large number of recurrent bleedings occurs in the first few hours, aneurysm occlu-
sion needs to be ultra-early, which remains challenging, especially when patients need to be
transferred to specialized treatment centers[16]. To overcome the problem of ultra-early recur-
rent bleedings, antifibrinolytic agents, such as TXA or epsilon-aminocaproic acid (EACA),
have been extensively investigated in the past. Although the recurrent bleeding risk is reduced
by TXA treatment, a concomitant increase in delayed ischemic deficits and thrombotic com-
plications leads to no significant net improvement in clinical outcome[10], [17]). The study by
Hillman[9] with short-term (up to 72 hours) treatment with antifibrinolytic therapy, however,
showed promising results with less recurrent bleedings and no significant increase in ischemic
neurological deficits. To date, the controversy remains regarding a beneficial effect on clinical
outcome of antifibrinolytic agents.
Our study differs from previously reported studies, because it combines two high volume
treatment centers with comparable SAH treatment protocols, but different approaches to the
Table 3. Patient outcome by treatmentgroup and adjusted per center with or without TXA treatment.
TXA Group (%)
N = 119
Standard Group (%)
N = 390
Total (%)
N = 509
OR (95% CI) aOR (95% CI)
In hospital mortality
(N = 509)
19 (16) 97 (25) 116 (23) 0.57 (0.33–0.98) 0.42 (0.22–0.80)
Poor outcome
(N = 481)
37 (34) 149 (40) 186 (39) 0.76 (0.48–1.18) 0.81 (0.45–1.44)
mRS 4 and 5
(N = 481)
14 (16) 44 (17) 58 (16) 0.97 (0.50–1.87) 2.59 (0.81–8.31)
LOS (days)#
(N = 386)
16 (11–29) 17 (11–26) 16 (11–27) 1.00 (0.99–1.01) 1.02 (0.99–1.04)
Discharge location#
(N = 389)
Home 36 (37) 119 (41) 155 (40) 0.84 (0.52–1.35) 0.74 (0.39–1.40)
Other hospital 34 (35) 120 (41) 154 (40) 0.76 (0.47–1.22) 0.87 (0.46–1.67)
Rehabilitation 12 (12) 35 (12) 47 (12) 1.02 (0.51–2.06) 0.70 (0.29–1.69)
Nursing home 15 (15) 13 (5) 28 (7) 3.86 (1.77–8.45) N/A�
Other 1 (1) 4 (1) 5 (1) 0.74 (0.08–6.70) N/A�
Permanent Shunt#
(N = 467)
18 (19) 46 (12) 64 (14) 1.68 (0.93–3.07) 1.66 (0.72–3.83)
N (%) unless otherwise stated.
�adjustments could not be made due to the low number of patients.
# numbers based on survivors
https://doi.org/10.1371/journal.pone.0211868.t003
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use of TXA. The strength of our study is that we increased power by pooling data of large treat-
ment centers with comparable treatment protocols with different use of TXA, making our
results more generally interpretable. Furthermore, due to the collection of intervals between
ictus-admission and time to treatment the two treatment protocols could be more exactly
compared, especially in respect to “preventable” early recurrent bleeding with TXA.
Surprisingly, TXA treatment did not significantly reduce recurrent bleedings in our study.
This could be explained by the fact that TXA treatment was only started after arrival in both
treatment centers, whereas most recurrent bleeding events occurred during transport or when
patients were still in the referring hospital as almost half of all recurrent bleedings are known
to occur within the first three hours after diagnosis[1]. It could also be caused by lack of power
because recurrent bleeding is relatively. We found that TXA treatment was associated with a
significant decrease in mortality. Furthermore TXA treatment showed a trend towards an
increase in favorable outcome, which is comparable to previous studies that administered anti-
fibrinolytic agents early and for a maximum of 72 hours[18]. This demonstrates that besides
short-term treatment with antifibrinolytics, as previously promoted in the literature[19], [18],
an ultra-early TXA treatment protocol could potentially lead to better outcomes.
To address this question therefore, a multicenter randomized controlled trial[11] (RCT)
was developed and is currently enrolling patients.
Noteworthy, with this short-term TXA treatment, there was no increase in the occurrence
of ischemic or thromboembolic complications, nor was there an increase in delayed cerebral
ischemia, in accordance to the recent literature [20]. In our study we found a low rate of sys-
temic thromboembolic complications compared to Foreman et.al.[17] and Starke et. al.[18].
All our patients were treated with prophylactic anticoagulation for DVT with additional com-
pression stockings with no routine screening for asymptomatic DVT.
The main limitations of our study are, first of all, that TXA administration times were col-
lected retrospectively, although all other patient data was collected prospectively. Secondly,
although the center that had additional treatment with TXA in its protocol, only two third of
the patients were actually treated with TXA, leading to a ratio (TXA vs standard group) of one
to three, and although no significant baseline differences were found, this might have intro-
duced a selection bias due to physician selection of initiation of additional TXA treatment.
Thirdly, in our cohort, recurrent bleeding percentages were comparable in both groups. One
explanation for the lack of reduction in recurrent bleeding is, that TXA treatment was started
only in the treatment center and not as early as possible in the referring hospital, thus exposing
patients to ultra-early recurrent bleeding during stay in referring hospitals or during transfers.
Although recurrent bleeding were similar we found a significantly decrease in mortality in the
TXA group due to less severe recurrent bleeding. Unfortunately no volume data on recurrent
bleeding was collected thus this remains a hypothetical explanation but should be addressed in
further studies. Lastly, modified Rankin scale scores were not scored in the same standardized
fashion in both centers. One of the treatment centers performed the standardized and vali-
dated telephone interview by trained and experienced research nurses, whereas the other cen-
ter based the mRS score at six months on doctors’ experience and patient-reported
functioning, as noted in the electronic patient records. Therefore, interpretation differences
could potentially have biased our results. However, by dichotomizing the mRS into good
(mRS 0–3) and poor (mRS 4–6), this interpretation bias should be minimal.
Conclusion
We found that TXA treatment was associated with a decrease in mortality and showed a trend
towards a better clinical outcome after six months in the group treated with short-term TXA.
Short-term tranexamic acid and aneurysmal subarachnoid hemorrhage
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No increase in thromboembolic complications was seen in TXA treatment. Evaluation of
ultra-early (at first diagnosis) and short-term (<24 h) TXA administration in a randomized
larger population is needed to assess the beneficial effect on outcome in aSAH patients.
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